Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

Core Viewpoint - Kamada Ltd. forecasts continued double-digit profitable growth for 2026, projecting revenues of $200 million - $205 million and adjusted EBITDA of $50 million - $53 million, based on organic growth of its commercial products portfolio [1][5][9] Financial Guidance - The 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA compared to the mid-points of 2025 guidance [1][5] - Kamada affirms its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million in adjusted EBITDA, with an expected year-end cash of approximately $75 million [1][5][9] Business Development and Growth Strategy - The company aims to drive growth through the expansion of its commercial product portfolio, including increased U.S. sales and sales of key products like KAMRAB®, GLASSIA®, HEPAGAM®, and VARIZIG® in international markets [2][3] - Kamada plans to enhance its Distribution segment by launching additional biosimilar products in Israel and expanding into the MENA region, alongside initial sales of normal source plasma collected in Texas [2][3] - The company is focused on identifying new business development and M&A opportunities to enrich its product portfolio and generate operational synergies [3][8] Operational Strength - Kamada emphasizes its ability to convert adjusted EBITDA into operational cash consistently, indicating strong financial health [2] - The company operates three plasma collection centers in the U.S. to support revenue growth through the sale of normal source plasma and to meet increasing demand for hyper-immune plasma [8]